Lancet · 2017

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR, OAK Study Group.

Show affiliations
  • Rittmeyer A — Lungenfachklinik Immenhausen, Immenhausen, Germany.
  • Barlesi F — Aix Marseille Universite, Assistance Publique Hôpitaux de Marseille, Marseille, France.
  • Waterkamp D — Genentech, Inc., South San Francisco, CA, USA.
  • Park K — Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Ciardiello F — Seconda Università degli Studi di Napoli, Napoli, Italy.
  • von Pawel J — Asklepios Fachkliniken München-Gauting, Gauting, Germany.
  • Gadgeel SM — Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  • Hida T — Aichi Cancer Center Hospital, Nagoya, Japan.
  • Kowalski DM — Oncology Centre, Institute M Sklodowska-Curie, Warsaw, Poland.
  • Dols MC — Medical Oncology Section, Hospital Regional Universitario Carlos Haya, Málaga, Spain.
  • Cortinovis DL — Medical Oncology Unit, AOU San Gerardo, Monza, Italy.
  • Leach J — Minnesota Oncology, Minneapolis, MN, USA.
  • Polikoff J — Southern California Permanente Medical Group, San Diego, CA, USA.
  • Barrios C — PUCRS School of Medicine, Porto Alegre, Brazil.
  • Kabbinavar F — University of California, Los Angeles, Los Angeles, CA, USA.
  • Frontera OA — Centro Internacional de Estudios Clinicos, Santiago, Chile.
  • De Marinis F — European Institute of Oncology, Milan, Italy.
  • Turna H — Istanbul University Cerrahpasa Medical Faculty Hospital, Medical Oncology, Istanbul, Turkey.
  • Lee JS — Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Ballinger M — Genentech, Inc., South San Francisco, CA, USA.
  • Kowanetz M — Genentech, Inc., South San Francisco, CA, USA.
  • He P — Genentech, Inc., South San Francisco, CA, USA.
  • Chen DS — Genentech, Inc., South San Francisco, CA, USA.
  • Sandler A — Genentech, Inc., South San Francisco, CA, USA.
  • Gandara DR — UC Davis Comprehensive Cancer Center, Sacramento, CA, USA. Electronic address: drgandara@ucdavis.edu.
52 read9 want to readRigor 3.1Novelty 2.9Impact 3.1Reprod. 3.0

Most-cited papers citing this

  • EBioMedicine · 2026 · cited by 7
  • J Hematol Oncol · 2026 · cited by 4
  • Chin Med J (Engl) · 2026 · cited by 4
  • Cancer Immunol Immunother · 2026 · cited by 3
  • J Clin Invest · 2026 · cited by 2

Log in to like, log, and share thoughts on this paper.

Discussion

Share your thoughts above to start a thread. Constructive feedback only — reply to and like others’ posts.

0

Yuki Sato

Rigor 4/5Novelty 1/5Impact 2/5Reprod. 5/5

Solid methods, convincing results.

0

Lena Khan

Rigor 2/5Novelty 5/5Impact 3/5Reprod. 3/5

Replication is unclear to me.

0

Mei Cohen

Rigor 5/5Novelty 2/5Impact 4/5Reprod. 1/5

Replication is unclear to me.

0

Ravi Cohen

Rigor 5/5Novelty 1/5Impact 4/5Reprod. 4/5

Interesting idea, small sample.

0

Eva Kim

Rigor 1/5Novelty 3/5Impact 1/5Reprod. 3/5

Solid methods, convincing results.

0

Ken Garcia

Rigor 5/5Novelty 5/5Impact 5/5Reprod. 4/5

Replication is unclear to me.

0

Liam Patel

Rigor 1/5Novelty 2/5Impact 5/5Reprod. 5/5

Important contribution to the field.

0

Nadia Lee

Rigor 3/5Novelty 5/5Impact 2/5Reprod. 3/5

Great figures and clear story.

0

Ines Garcia

Rigor 1/5Novelty 1/5Impact 1/5Reprod. 1/5

Great figures and clear story.

0

Mei Lee

Rigor 3/5Novelty 1/5Impact 2/5Reprod. 4/5

Great figures and clear story.